Aquestive Therapeutics (AQST) Total Non-Current Liabilities (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Total Non-Current Liabilities of $169.1 million for Q1 2026, up 5.08% year-over-year from $160.9 million in Q1 2025, and down 9.47% quarter-over-quarter from $186.8 million in Q4 2025.
Aquestive Therapeutics (AQST) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $169.1 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 5.08% year-over-year to $169.1 million; the TTM figure through Mar 2026 stood at $169.1 million (up 5.08% YoY), while the FY2025 annual figure was $186.8 million, up 17.36% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $169.1 million, down from $186.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $186.8 million in Q4 2025, with the low at $147.8 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $161.6 million (2023), against an average of $162.1 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 32.02% in 2022, then slipped 6.74% in 2023.
- Aquestive Therapeutics' Total Non-Current Liabilities stood at $173.6 million in 2022, then slipped by 6.74% to $161.9 million in 2023, then slipped by 1.67% to $159.2 million in 2024, then climbed by 17.36% to $186.8 million in 2025, then slipped by 9.47% to $169.1 million in 2026.
- Business Quant data shows AQST's Total Non-Current Liabilities at $169.1 million in Q1 2026, $186.8 million in Q4 2025, and $165.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 334.00 Mn |
| 10 | Aquestive Therapeutics | 551.85 Mn | 551.85 Mn | 9.80 Mn | 182.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 182.51 Mn |
| Mar 31, 2026 | 169.13 Mn |
| Dec 31, 2025 | 186.82 Mn |
| Sep 30, 2025 | 165.61 Mn |
| Jun 30, 2025 | 164.24 Mn |
| Mar 31, 2025 | 160.95 Mn |
| Dec 31, 2024 | 159.19 Mn |
| Sep 30, 2024 | 153.35 Mn |
| Jun 30, 2024 | 151.06 Mn |
| Mar 31, 2024 | 163.80 Mn |
| Dec 31, 2023 | 161.89 Mn |
| Sep 30, 2023 | 160.36 Mn |
| Jun 30, 2023 | 161.64 Mn |
| Mar 31, 2023 | 168.46 Mn |
| Dec 31, 2022 | 173.59 Mn |
| Sep 30, 2022 | 157.51 Mn |
| Jun 30, 2022 | 150.29 Mn |
| Mar 31, 2022 | 147.81 Mn |
| Dec 31, 2021 | 141.64 Mn |
| Sep 30, 2021 | 123.83 Mn |